VERTEX PHARMACEUTICALS INC / MA 4
4 · VERTEX PHARMACEUTICALS INC / MA · Filed Feb 7, 2014
Insider Transaction Report
Form 4
Pace Megan E
SVP, Corp. Communications
Transactions
- Award
Common Stock
2014-02-05$0.01/sh+14,250$143→ 24,350 total - Award
Employee Stock Option (right to buy)
2014-02-05+55,000→ 55,000 totalExercise: $77.31Exp: 2024-02-04→ Common Stock (55,000 underlying)
Footnotes (2)
- [F1]Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2018, subject to (i) acceleration of 50% of shares upon (a) reaching a specified net product sales level over a one-year period for a combination regimen that includes ivacaftor and a CFTR corrector or (b) dosing of the first patient in the first clinical trial to evaluate a second-generation CFTR corrector compound and (ii) acceleration of 50% of shares upon (a) dosing of the first patient in a pivotal trial for a regimen including VX-661 or a specified cancer compound or (b) reaching a specified net product sales level over a one-year period for all our products.
- [F2]The option vests in 16 quarterly installments from 02/05/2014.